1. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
   Jian-Wei Zhang et al, 2015, Chin J Cancer CrossRef
2. null
   Maria Li Lung et al, 2019 CrossRef
3. HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma.
   Xianyue Ren et al, 2017, Nat Commun CrossRef
4. Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma
   Yock Ping Chow et al, 2017, Sci Rep CrossRef
5. Nasopharyngeal Cancer: Molecular Landscape
   Jeff P. Bruce et al, 2015, JCO CrossRef
6. MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine
   Tania Fleitas et al, 2016, Cancer Treatment Reviews CrossRef
7. Prevalent somaticBRCA1mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe
   George Fountzilas et al, 2018, Int. J. Cancer CrossRef
8. Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma.
   Engku Nur Syafirah E A R et al, 2020, Diagnostics (Basel) CrossRef
9. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma
   Jianbin Zhang et al, 2021, European Journal of Pharmacology CrossRef
10. The Role of Epstein-Barr Virus in Modulating Key Tumor Suppressor Genes in Associated Malignancies: Epigenetics, Transcriptional, and Post-Translational Modifications
    Adelaide Ohui Fierti et al, 2022, Biomolecules CrossRef
11. EGFR Mutation in Nasopharyngeal Carcinoma
    Evren Uzun et al, 2022, JMP CrossRef
12. Repression of DERL3 via DNA methylation by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma
    Satoru Kondo et al, 2022, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
13. The molecular march of primary and recurrent nasopharyngeal carcinoma.
    Nicholas J Campion et al, 2021, Oncogene CrossRef
14. Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor
    Jiangping Li et al, 2023 CrossRef
15. Establishment and Characterization of an Epstein-Barr Virus–positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma
    Annie Wai Yeeng Chai et al, 2024 CrossRef
16. Combining Mefloquine with an Mcl-1 Inhibitor as a Novel Therapeutic Strategy for the Treatment of Nasopharyngeal Carcinoma
    Jiaqi Dong et al, 2024, Nutrition and Cancer CrossRef